薄芝糖肽对乳腺癌化疗患者的免疫增强、减毒作用  

The immune enhancement and rudcing side effects of Polysaccharide kureha on patients with breast cancer treated by chemotherapy

作　　者：孙宇[1] 邹燕鹏[1] 尹宝娇 张树平[1] 盛洁[1] 钱鹏飞[1] 董菊红[1] 闻国权[1] 

机构地区：[1]广州医科大学附属惠州医院乳腺中心,广东惠州516002

出　　处：《现代肿瘤医学》2016年第2期242-245,共4页Journal of Modern Oncology

基　　金：惠州市科技计划项目(编号:2013Y149)

摘　　要：目的:对薄芝糖肽降低乳腺癌术后TE方案化疗的毒副反应及增强化疗患者免疫力进行研究。方法:将80例乳腺浸润导管癌患者随机分成化疗联合薄芝糖肽治疗组和单纯接受化疗组。对比治疗组和单纯化疗组患者化疗前后的生活质量及化疗后胃肠毒性、血液毒性、肝脏毒性;比较治疗前后两组外周血T淋巴细胞亚群(包括CD3+、CD4+、CD8+淋巴细胞和CD4+/CD8+比值)变化。结果:治疗后两组生活质量较治疗前均有所下降(P<0.05),但治疗组患者生活质量优于对照组(P<0.05)。治疗组的血液毒性、胃肠道毒性均低于对照组(P<0.05);两组肝脏毒性比较差异无统计学意义(P>0.05);治疗后两组T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+比值)比较差异有统计学意义(P<0.05)。结论:薄芝糖肽不仅可以提高患者生活质量,减轻化疗患者的血液毒性和胃肠道毒性,而且不会增加患者肝功能损害,并可改善化疗患者T淋巴细胞亚群细胞水平免疫。Objective： To study the immune enhancement and rudcing side effects of patients with breast cancer chemotherapy after treating with Polysaccharide kureha. Methods： All 80 patients with breast invasive ductal carcinoma were randomly divided into chemotherapy combined Polysaccharide kureha treatment group and single chemotherapy group. Comparing the quality of life,gastrointestinal toxicity,blood toxicity,liver toxicity of two group＇s,and T lymphocyte subsets（ CD3^＋,CD4^＋,CD8^＋lymphocytes and CD4^＋/ CD8^＋ratio）. Results： The quality of life of the two group reduced after chemotherapy（ P〈0. 05）,but the treatment group life quality was better than control group（ P〈0. 05）. The blood toxicity,gastrointestinal toxicity of treatment group were better than control group（ P〈0. 05）. The liver toxicity was similar between the two groups（ P〈0. 05）. The T lymphocyte subsets（ CD3^＋,CD4^＋,CD4^＋/ CD8^＋ratio） of two groups after treatment was statistically significant（ P〈0. 05）. Conclusion： Polysaccharide kureha can improve the patients quality of life,reduce the blood toxicity and gastrointestinal toxicity,improve T lymphocyte subsets in patients with chemotherapy,and doesn＇ t increase liver function damage.

关 键 词：薄芝糖肽 乳腺癌 化疗 免疫力 

分 类 号：R737.9[医药卫生—肿瘤]